EHA 2026 | Advances and ongoing challenges in chronic myeloid leukemia management
Jorge Cortes
• 12 Jun 2026
Jorge Cortes, MD, The University of Alabama at Birmingham, Birmingham, AL, discusses the major advances and ongoing challenges in chronic myeloid leukemia (CML). Dr Cortes reviews the long-term impact of tyrosine kinase inhibitors (TKIs), the emergence of newer therapies, and the remaining unmet needs related to treatment-free remission, tolerability, and quality of life (QoL) for patients with CML. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
